[Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
Kulp
Werner
W
Institut für Versicherungsbetriebslehre Universität Hannover Königsworther Platz 1 30167 Hannover. wk@ivbl.uni-hannover.de
Greiner
Wolfgang
W
Graf von der Schulenburg
J Matthias
JM
D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D005858:Germany; D006801:Humans; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha